Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2008

Open Access 01-08-2008 | Research article

The renal metallothionein expression profile is altered in human lupus nephritis

Authors: Mikkel Faurschou, Milena Penkowa, Claus Bøgelund Andersen, Henrik Starklint, Søren Jacobsen

Published in: Arthritis Research & Therapy | Issue 4/2008

Login to get access

Abstract

Introduction

Metallothionein (MT) isoforms I + II are polypeptides with potent antioxidative and anti-inflammatory properties. In healthy kidneys, MT-I+II have been described as intracellular proteins of proximal tubular cells. The aim of the present study was to investigate whether the renal MT-I+II expression profile is altered during lupus nephritis.

Methods

Immunohistochemistry was performed on renal biopsies from 37 patients with lupus nephritis. Four specimens of healthy renal tissue served as controls. Clinicopathological correlation studies and renal survival analyses were performed by means of standard statistical methods.

Results

Proximal tubules displaying epithelial cell MT-I+II depletion in combination with luminal MT-I+II expression were observed in 31 out of 37 of the lupus nephritis specimens, but not in any of the control sections (P = 0.006). The tubular MT score, defined as the median number of proximal tubules displaying this MT expression pattern per high-power microscope field (40× magnification), was positively correlated to the creatinine clearance in the lupus nephritis cohort (P = 0.01). Furthermore, a tubular MT score below the median value of the cohort emerged as a significant predictor of a poor renal outcome in renal survival analyses. Thus, patients with a tubular MT score < 1.0 had a 6.2-times higher risk of developing end-stage renal disease than patients with a tubular MT score ≥ 1.0 (P = 0.03).

Conclusion

Lupus nephritis is associated with significant alterations in renal MT-I+II expression. Our data indicate that important prognostic information can be deduced from the renal MT-I+II expression profile in systemic lupus erythematosus patients with nephritis.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference MacGowan JR, Ellis S, Griffiths M, Isenberg DA: Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford). 2002, 41: 981-987. 10.1093/rheumatology/41.9.981.CrossRef MacGowan JR, Ellis S, Griffiths M, Isenberg DA: Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford). 2002, 41: 981-987. 10.1093/rheumatology/41.9.981.CrossRef
3.
go back to reference Martins L, Rocha G, Rodrigues A, Santos J, Vasconcelos C, Correia J, Farinha F, Almeida I, Barbosa P, Guimaraes S: Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol. 2002, 57: 114-119.CrossRefPubMed Martins L, Rocha G, Rodrigues A, Santos J, Vasconcelos C, Correia J, Farinha F, Almeida I, Barbosa P, Guimaraes S: Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol. 2002, 57: 114-119.CrossRefPubMed
4.
go back to reference Faurschou M, Starklint H, Halberg P, Jacobsen S: Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006, 33: 1563-1569.PubMed Faurschou M, Starklint H, Halberg P, Jacobsen S: Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006, 33: 1563-1569.PubMed
5.
go back to reference Davidson A, Aranow C: Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006, 18: 468-475.PubMed Davidson A, Aranow C: Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006, 18: 468-475.PubMed
6.
go back to reference Penkowa M: Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J. 2006, 273: 1857-1870. 10.1111/j.1742-4658.2006.05207.x.CrossRefPubMed Penkowa M: Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J. 2006, 273: 1857-1870. 10.1111/j.1742-4658.2006.05207.x.CrossRefPubMed
7.
go back to reference Carrasco J, Penkowa M, Hadberg H, Molinero A, Hidalgo J: Enhanced seizures and hippocampal neurodegeneration following kainic acid-induced seizures in metallothionein-I + II-deficient mice. Eur J Neurosci. 2000, 12: 2311-2322. 10.1046/j.1460-9568.2000.00128.x.CrossRefPubMed Carrasco J, Penkowa M, Hadberg H, Molinero A, Hidalgo J: Enhanced seizures and hippocampal neurodegeneration following kainic acid-induced seizures in metallothionein-I + II-deficient mice. Eur J Neurosci. 2000, 12: 2311-2322. 10.1046/j.1460-9568.2000.00128.x.CrossRefPubMed
8.
go back to reference Giralt M, Penkowa M, Hernandez J, Molinero A, Carrasco J, Lago N, Camats J, Campbell IL, Hidalgo J: Metallothionein-1+2 deficiency increases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. Neurobiol Dis. 2002, 9: 319-338. 10.1006/nbdi.2002.0480.CrossRefPubMed Giralt M, Penkowa M, Hernandez J, Molinero A, Carrasco J, Lago N, Camats J, Campbell IL, Hidalgo J: Metallothionein-1+2 deficiency increases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. Neurobiol Dis. 2002, 9: 319-338. 10.1006/nbdi.2002.0480.CrossRefPubMed
9.
go back to reference Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J: Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res. 2005, 79: 522-534. 10.1002/jnr.20387.CrossRefPubMed Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J: Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res. 2005, 79: 522-534. 10.1002/jnr.20387.CrossRefPubMed
10.
go back to reference Li X, Chen H, Epstein PN: Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem. 2004, 279: 765-771. 10.1074/jbc.M307907200.CrossRefPubMed Li X, Chen H, Epstein PN: Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem. 2004, 279: 765-771. 10.1074/jbc.M307907200.CrossRefPubMed
11.
go back to reference Youn J, Lynes MA: Metallothionein-induced suppression of cytotoxic T lymphocyte function: an important immunoregulatory control. Toxicol Sci. 1999, 52: 199-208. 10.1093/toxsci/52.2.199.CrossRefPubMed Youn J, Lynes MA: Metallothionein-induced suppression of cytotoxic T lymphocyte function: an important immunoregulatory control. Toxicol Sci. 1999, 52: 199-208. 10.1093/toxsci/52.2.199.CrossRefPubMed
12.
go back to reference Lynes MA, Borghesi LA, Youn J, Olson EA: Immunomodulatory activities of extracellular metallothionein. I. Metallothionein effects on antibody production. Toxicology. 1993, 85: 161-177. 10.1016/0300-483X(93)90040-Y.CrossRefPubMed Lynes MA, Borghesi LA, Youn J, Olson EA: Immunomodulatory activities of extracellular metallothionein. I. Metallothionein effects on antibody production. Toxicology. 1993, 85: 161-177. 10.1016/0300-483X(93)90040-Y.CrossRefPubMed
13.
go back to reference Nartey NO, Banerjee D, Cherian MG: Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and kidney and its changes during development. Pathology. 1987, 19: 233-238. 10.3109/00313028709066555.CrossRefPubMed Nartey NO, Banerjee D, Cherian MG: Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and kidney and its changes during development. Pathology. 1987, 19: 233-238. 10.3109/00313028709066555.CrossRefPubMed
14.
go back to reference Mididoddi S, McGuirt JP, Sens MA, Todd JH, Sens DA: Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett. 1996, 85: 17-27. 10.1016/0378-4274(96)03632-6.CrossRefPubMed Mididoddi S, McGuirt JP, Sens MA, Todd JH, Sens DA: Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett. 1996, 85: 17-27. 10.1016/0378-4274(96)03632-6.CrossRefPubMed
15.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed
16.
go back to reference Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, d'Ascanio A, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 527-539.PubMed Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, d'Ascanio A, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 527-539.PubMed
17.
go back to reference Churg J, Sobin LH: Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin. 1982, 127-131. Churg J, Sobin LH: Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin. 1982, 127-131.
18.
go back to reference Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983, 75: 382-391. 10.1016/0002-9343(83)90338-8.CrossRefPubMed Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983, 75: 382-391. 10.1016/0002-9343(83)90338-8.CrossRefPubMed
19.
go back to reference Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J: Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia. 2000, 32: 271-285. 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5.CrossRefPubMed Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J: Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia. 2000, 32: 271-285. 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5.CrossRefPubMed
20.
go back to reference Penkowa M, Hidalgo J, Moos T: Increased astrocytic expression of metallothioneins I + II in brainstem of adult rats treated with 6-aminonicotinamide. Brain Res. 1997, 774: 256-259. 10.1016/S0006-8993(97)81716-7.CrossRefPubMed Penkowa M, Hidalgo J, Moos T: Increased astrocytic expression of metallothioneins I + II in brainstem of adult rats treated with 6-aminonicotinamide. Brain Res. 1997, 774: 256-259. 10.1016/S0006-8993(97)81716-7.CrossRefPubMed
21.
go back to reference Gasull T, Rebollo DV, Romero B, Hidalgo J: Development of a competitive double antibody radioimmunoassay for rat metallothionein. J Immunoassay. 1993, 14: 209-225. 10.1080/15321819308019851.CrossRefPubMed Gasull T, Rebollo DV, Romero B, Hidalgo J: Development of a competitive double antibody radioimmunoassay for rat metallothionein. J Immunoassay. 1993, 14: 209-225. 10.1080/15321819308019851.CrossRefPubMed
22.
go back to reference Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, Bluethmann H, Hidalgo J: Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia. 1999, 25: 343-357. 10.1002/(SICI)1098-1136(19990215)25:4<343::AID-GLIA4>3.0.CO;2-V.CrossRefPubMed Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, Bluethmann H, Hidalgo J: Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia. 1999, 25: 343-357. 10.1002/(SICI)1098-1136(19990215)25:4<343::AID-GLIA4>3.0.CO;2-V.CrossRefPubMed
23.
go back to reference Penkowa M, Espejo C, Ortega-Aznar A, Hidalgo J, Montalban X, Martinez Caceres EM: Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci. 2003, 60: 1258-1266.CrossRefPubMed Penkowa M, Espejo C, Ortega-Aznar A, Hidalgo J, Montalban X, Martinez Caceres EM: Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci. 2003, 60: 1258-1266.CrossRefPubMed
24.
go back to reference Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol. 1997, 8: 1537-1545.PubMed Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol. 1997, 8: 1537-1545.PubMed
25.
go back to reference Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int. 1998, 53: 1608-1615. 10.1046/j.1523-1755.1998.00905.x.CrossRefPubMed Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int. 1998, 53: 1608-1615. 10.1046/j.1523-1755.1998.00905.x.CrossRefPubMed
26.
go back to reference Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, Lai KN: Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest. 2003, 111: 515-527.PubMedCentralCrossRefPubMed Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, Lai KN: Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest. 2003, 111: 515-527.PubMedCentralCrossRefPubMed
27.
go back to reference Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH: Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol. 1999, 10: 69-76.PubMed Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH: Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol. 1999, 10: 69-76.PubMed
28.
go back to reference Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G: Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int. 2002, 61: 2066-2077. 10.1046/j.1523-1755.2002.00380.x.CrossRefPubMed Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G: Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int. 2002, 61: 2066-2077. 10.1046/j.1523-1755.2002.00380.x.CrossRefPubMed
29.
go back to reference Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G: Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 2007, 56: 1569-1578. 10.1002/art.22524.CrossRefPubMed Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G: Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 2007, 56: 1569-1578. 10.1002/art.22524.CrossRefPubMed
30.
go back to reference Daniel L, Sichez H, Giorgi R, Dussol B, Figarella-Branger D, Pellissier JF, Berland Y: Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 2001, 60: 2215-2221. 10.1046/j.1523-1755.2001.00055.x.CrossRefPubMed Daniel L, Sichez H, Giorgi R, Dussol B, Figarella-Branger D, Pellissier JF, Berland Y: Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 2001, 60: 2215-2221. 10.1046/j.1523-1755.2001.00055.x.CrossRefPubMed
31.
go back to reference Illei GG, Lipsky PE: Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep. 2004, 6: 382-390. 10.1007/s11926-004-0013-4.CrossRefPubMed Illei GG, Lipsky PE: Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep. 2004, 6: 382-390. 10.1007/s11926-004-0013-4.CrossRefPubMed
32.
go back to reference Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C: Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007, 179: 7166-7175.CrossRefPubMed Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C: Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007, 179: 7166-7175.CrossRefPubMed
33.
go back to reference Derksen RH, Hene RJ, Kater L: The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center. Lupus. 1992, 1: 97-103. 10.1177/096120339200100207.CrossRefPubMed Derksen RH, Hene RJ, Kater L: The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center. Lupus. 1992, 1: 97-103. 10.1177/096120339200100207.CrossRefPubMed
34.
go back to reference Ravinal RC, Costa RS, Coimbra TM, Pastorello MT, Coelho EB, Dantas M, dos RM: Classes, activity and chronicity indices, and alpha-smooth muscle actin expression as prognostic parameters in lupus nephritis outcome. Lupus. 2002, 11: 82-87. 10.1191/0961203302lu153oa.CrossRefPubMed Ravinal RC, Costa RS, Coimbra TM, Pastorello MT, Coelho EB, Dantas M, dos RM: Classes, activity and chronicity indices, and alpha-smooth muscle actin expression as prognostic parameters in lupus nephritis outcome. Lupus. 2002, 11: 82-87. 10.1191/0961203302lu153oa.CrossRefPubMed
35.
go back to reference Austin HA, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995, 10: 1620-1628.PubMed Austin HA, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995, 10: 1620-1628.PubMed
36.
go back to reference Austin HA, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994, 45: 544-550. 10.1038/ki.1994.70.CrossRefPubMed Austin HA, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994, 45: 544-550. 10.1038/ki.1994.70.CrossRefPubMed
37.
go back to reference Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, Fleming JA, Howell DN: Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol. 1996, 46: 170-175.PubMed Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, Fleming JA, Howell DN: Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol. 1996, 46: 170-175.PubMed
38.
go back to reference Klaassen CD, Liu J, Choudhuri S: Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 1999, 39: 267-294. 10.1146/annurev.pharmtox.39.1.267.CrossRefPubMed Klaassen CD, Liu J, Choudhuri S: Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 1999, 39: 267-294. 10.1146/annurev.pharmtox.39.1.267.CrossRefPubMed
39.
go back to reference Ogra Y, Suzuki KT: Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. Cell Mol Biol (Noisy-le-grand). 2000, 46: 357-365. Ogra Y, Suzuki KT: Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. Cell Mol Biol (Noisy-le-grand). 2000, 46: 357-365.
40.
go back to reference Chung RS, West AK: A role for extracellular metallothioneins in CNS injury and repair. Neuroscience. 2004, 123: 595-599. 10.1016/j.neuroscience.2003.10.019.CrossRefPubMed Chung RS, West AK: A role for extracellular metallothioneins in CNS injury and repair. Neuroscience. 2004, 123: 595-599. 10.1016/j.neuroscience.2003.10.019.CrossRefPubMed
Metadata
Title
The renal metallothionein expression profile is altered in human lupus nephritis
Authors
Mikkel Faurschou
Milena Penkowa
Claus Bøgelund Andersen
Henrik Starklint
Søren Jacobsen
Publication date
01-08-2008
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2008
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2450

Other articles of this Issue 4/2008

Arthritis Research & Therapy 4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.